Depomed (DEPO) Wins Order Obtaining Injunction vs. Defendants Over Generic Nucynta (AGN)

September 30, 2016 3:19 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Depomed (Nasdaq: DEPO) wins order obtaining injunction blocking generic version of Nucynta, according to Bloomberg.

Allergan (NYSE: AGN) can't sell generic Nucynta pending final judgment. Actavis, Roxane also lost an effort to invalidate Nucynta patents.

Depomed's patents on Nucynta expire between 2022 and 2028.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Hot Corp. News, Litigation, Trader Talk

Add Your Comment